Retatrutide, also known by the development code LY3437943, is an investigational peptide studied for activity at three hormone receptors: GIP, GLP-1, and glucagon. That design is why it is often called a triple agonist. This guide explains the receptor concept, summarizes the published research record, and separates clinical-trial findings from claims about any research material.
What Is Retatrutide?
Retatrutide is the development name for LY3437943, a peptide drug candidate being studied by Eli Lilly. It is one molecule designed to activate the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. The three-target design is its defining research feature.
Words such as “triple agonist” describe the proposed receptor activity. They do not, by themselves, tell us how a molecule will perform in every tissue, assay, or clinical setting. For that, the study design and measured endpoints matter.
How Is Retatrutide Designed to Work?
Researchers study retatrutide at GIP, GLP-1, and glucagon receptors. Each receptor belongs to a hormone-signaling system involved in metabolic biology. An agonist is a molecule that activates a receptor; the size and type of response depend on the biological system being tested.
Laboratory findings are shaped by the cell model, receptor expression, assay method, concentration range, and analysis choices. A result from one experimental setup should not be assumed to predict a result in another. Clear papers report those conditions so readers can judge what the data support.
How Retatrutide Differs from Semaglutide and Tirzepatide
| Molecule | Receptor activity described in research |
|---|---|
| Semaglutide | GLP-1 receptor agonist |
| Tirzepatide | GIP and GLP-1 receptor agonist |
| Retatrutide | Designed to activate GIP, GLP-1, and glucagon receptors |
This is a comparison of receptor design, not a ranking of treatments or outcomes. Studies with different participants, protocols, and endpoints cannot establish which molecule is better for an individual. See our separate Retatrutide and semaglutide research comparison for a closer look at how to read those differences.
What Has Clinical Research Reported?
The first widely cited obesity study was a Phase 2 randomized trial published in the New England Journal of Medicine in 2023. A separate Phase 2 study examined retatrutide in adults with type 2 diabetes. These papers describe results for the specific investigational formulation and participants enrolled in each study.
By 2026, the development program had advanced to Phase 3, and results from several Phase 3 studies had been reported. One Phase 3 obesity study has since been published in the New England Journal of Medicine. The linked research papers and Lilly's current development update provide the details. Sponsor announcements can be useful for tracking milestones, but they should be distinguished from full peer-reviewed papers.
Even when a trial reports a clear result, it applies to that trial's formulation, population, protocol, and follow-up period. Separate studies are not direct head-to-head comparisons unless they were designed and conducted as such.
What Can a Clinical Trial Tell You About a Research Sample?
A clinical trial studies a defined product made for that study. Its results do not authenticate a different vial, batch, supplier, or listing. To evaluate a laboratory material, researchers need lot-specific records and methods that fit the question being asked.
A name on a label, a product photograph, or a published trial result cannot establish the identity or quality of a separate sample. Keep claims about study products separate from claims about materials offered elsewhere.
How to Read Laboratory Documentation
Start by matching the lot identifier on the material to the identifier on its documentation. Then check which analytical method was used, what the result measures, and whether the report names its method conditions and reference material.
An HPLC purity percentage describes a chromatographic result under stated conditions. By itself, it does not establish molecular identity, sterility, endotoxin status, biological activity, or suitability for a particular experiment. Those questions may require additional methods. Documentation is evidence to assess, not a substitute for independent validation or an assay-specific quality review.
Current Development and FDA Status
As of October 6, 2026, retatrutide remains investigational and is not FDA approved. Eli Lilly reports that it is being studied in Phase 3 clinical trials. Approval status can change, so check current primary sources before relying on it.
The FDA states that retatrutide cannot be used in compounding under federal law and has warned about unapproved drugs labeled “for research purposes” or “not for human consumption” when they are marketed to consumers for human use. A research-use label does not make a product FDA approved or establish its quality.
Frequently Asked Questions
What is LY3437943?
LY3437943 is the development code for retatrutide.
What does “triple agonist” mean?
It describes retatrutide's designed activity at three receptors: GIP, GLP-1, and glucagon receptors. It is not the name of a separate hormone called “GLP-3.”
How is retatrutide different from tirzepatide?
Retatrutide is designed to activate GIP, GLP-1, and glucagon receptors. Tirzepatide is described as activating GIP and GLP-1 receptors. This difference describes receptor design, not comparative clinical benefit.
Is retatrutide FDA approved?
No. As of October 6, 2026, it remains investigational and is not FDA approved. Check Lilly and FDA sources for current status.
Does an HPLC purity result prove a material's identity?
No. It reports a chromatographic result under specific conditions. Identity and other quality questions need appropriate supporting methods and lot-specific documentation.
Can trial results verify a research-use sample?
No. A clinical trial evaluates its own investigational product. It cannot authenticate an unrelated sample or confirm the documentation for another batch.
Related Retatrutide Research and Laboratory Documentation
For product-specific research catalog information, see the RETA Research Peptide listing. Product descriptions do not establish the identity, purity, or suitability of any individual lot.
Continue with the scientific comparisons Retatrutide vs. Tirzepatide and Retatrutide vs. Semaglutide. Learn how to evaluate laboratory documentation in How to Read a Peptide COA.
HPLC purity, compound identity, and net peptide content are distinct analytical questions. Batch-specific claims require corresponding documentation. These materials are not intended for human use.
References
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 2023.
- Rosenstock et al. Retatrutide in people with type 2 diabetes: a Phase 2 randomized trial. The Lancet, 2023.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Phase 3 clinical research, 2026.
- ClinicalTrials.gov: TRIUMPH-1, NCT05929066.
- Eli Lilly: Current information about retatrutide and its investigational status.
- U.S. FDA: Concerns with unapproved GLP-1 drugs and retatrutide.
Reviewed October 6, 2026. For scientific information only. Not medical advice, diagnosis, or treatment.
Retatrutide identity and documentation checklist
Retatrutide literature describes an investigational molecule and its study context. A supplier listing describes a research material. Review both, but do not use a trial result as proof that an unrelated lot is authentic or suitable for a particular experiment.
Clinical-study context versus lot evidence
Record the study identifier, molecule name or alias, and the population or model described by the source. Separately record the research material’s lot, certificate, analytical methods, and report date. Keeping these records separate prevents evidence from being overstated.
Analytical documentation
HPLC purity, mass-spectrometry identity, net content, and other tests should be described by method and scope. A single purity value cannot answer every identity or composition question.
Continue the documentation review
Review the RETA product page, RETA research profile, COA guide, Learn hub, Peptide Research Library, and the shipping policy. These resources are for research documentation and catalog context only.
How does a lot-specific COA help?
It can connect a reported analytical result to a named batch. It does not replace independent verification or prove that a research material matches a clinical-study product.